CeriBell (NASDAQ:CBLL) CEO Xingjuan Chao Sells 6,030 Shares

CeriBell, Inc. (NASDAQ:CBLL) CEO Xingjuan Chao sold 6,030 shares of the company’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $18.00, for a total value of $108,540.00. Following the completion of the sale, the chief executive officer directly owned 830,317 shares of the company’s stock, valued at approximately $14,945,706. This trade represents a 0.72% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xingjuan Chao also recently made the following trade(s):

• On Tuesday, May 5th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $20.10, for a total value of $783,900.00.
• On Monday, April 6th, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $18.40, for a total value of $717,600.00.
• On Tuesday, March 3rd, Xingjuan Chao sold 39,000 shares of CeriBell stock. The stock was sold at an average price of $17.45, for a total value of $680,550.00.

CeriBell Price Performance

NASDAQ CBLL opened at $18.80 on Wednesday. The business has a 50 day simple moving average of $19.09 and a 200 day simple moving average of $19.24. CeriBell, Inc. has a 52-week low of $10.85 and a 52-week high of $24.33. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The stock has a market cap of $713.27 million, a price-to-earnings ratio of -11.53 and a beta of 0.99.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Monday, May 11th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative return on equity of 38.19% and a negative net margin of 63.51%.The business had revenue of $26.49 million for the quarter, compared to the consensus estimate of $26.09 million. Analysts anticipate that CeriBell, Inc. will post -1.69 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on CBLL shares. Weiss Ratings cut CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 12th. BTIG Research reissued a “buy” rating and set a $30.00 target price on shares of CeriBell in a research note on Wednesday, January 28th. Finally, Canaccord Genuity Group lowered their target price on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and a consensus price target of $22.20.

Hedge Funds Weigh In On CeriBell

Several hedge funds have recently made changes to their positions in CBLL. Bank of New York Mellon Corp grew its stake in shares of CeriBell by 1,945.9% during the 4th quarter. Bank of New York Mellon Corp now owns 1,221,927 shares of the company’s stock worth $26,797,000 after acquiring an additional 1,162,200 shares in the last quarter. KCM Capital Inc bought a new position in shares of CeriBell during the 4th quarter worth approximately $21,930,000. Royce & Associates LP bought a new position in shares of CeriBell during the 4th quarter worth approximately $11,695,000. Adage Capital Partners GP L.L.C. bought a new position in shares of CeriBell during the 4th quarter worth approximately $10,965,000. Finally, CenterBook Partners LP grew its stake in shares of CeriBell by 448.0% during the 3rd quarter. CenterBook Partners LP now owns 476,554 shares of the company’s stock worth $5,476,000 after acquiring an additional 389,584 shares in the last quarter.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.